Ignite Creation Date:
2024-05-06 @ 10:03 AM
Last Modification Date:
2024-10-26 @ 12:24 PM
Study NCT ID:
NCT03155009
Status:
COMPLETED
Last Update Posted:
2020-02-10
First Post:
2017-05-11
Brief Title:
A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase ALK-Rearranged Non-Small Cell Lung Cancer
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open-Label Multicenter Single-Arm Phase II Study to Assess the Efficacy and Safety of Alectinib in Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on Prior ALK Inhibitor Therapy
Status:
COMPLETED
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATALK
Brief Summary:
This study will evaluate the efficacy and safety of alectinib in selected participants with anaplastic lymphoma kinase-rearranged ALK-rearranged non-small cell lung cancer NSCLC after disease progression on prior treatment strategy with crizotinib as only ALK inhibitor and eventually chemotherapy treatments
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-003924-22 | EUDRACT_NUMBER | None | None |